Epidiolex, FDA’s first CBD drug, posts strong sales in its launch year

TRADELABOR has more than 20 years of experience in the control and treatment of air, working with an experienced and qualified technical staff and with the most advanced technology in this area, which together guarantee the quality of the services provided.

 

 

Preliminary sales figures for Epidiolex — the first FDA-backed cannabis-based medicine in the United States — suggest that the drug had a successful launch year. Epidiolex contains cannabidiol and is used to treat severe forms of epilepsy.

According to Justin Gover, CEO of GW Pharmaceuticals, during the fourth quarter of 2019, Epidiolex brought in total sales of US$ 104 million from the US and US$ 296 million from across the globe.

We build Industrial Site for Cannabis Oil Extraction. See more at:  PHARMAIUM

 

Contact us:  amg@pharmaium.com

“It’s an incredible launch year for any medication (that) I think proves that this kind of medicine is really making a difference to patients,” Gover told CNBC. It shows real value to the healthcare system, and it sets us up, I think, in a very nice way for what should be another great year for us in 2020.”

Cannabidiol, commonly known as CBD, is a component derived from the marijuana plant that doesn’t cause intoxication when consumed. The FDA approved Epidiolex in 2018, and the oral solution became available later that year for patients ages two and older with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy.

Last year, GW Pharmaceuticals received approval from the European Union to market the same drug as Epidiolex in 28 countries on the continent.

 

Continue at: https://www.pharmacompass.com/radio-compass-blog/cipla-in-fda-trouble-fda-backed-cannabis-drug-posts-strong-sales-in-launch-year

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:

www.manostaxx.com

 

Manostaxx
Manostaxx – Industrial Management Consulting

Leave a Reply

Your email address will not be published. Required fields are marked *